These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2084339)

  • 1. [Diagnosis and therapeutic correction of changes in the cardiovascular system of patients with prostatic cancer treated with estrogens].
    Gembitskiĭ EV; Portnoĭ AS; Begunov AV
    Klin Med (Mosk); 1990 Dec; 68(12):41-5. PubMed ID: 2084339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The assessment of the state of the blood lipid spectrum, hemostasis, hormonal homeostasis and hemodynamics in the early diagnosis and drug correction of the cardiovascular changes in prostatic cancer patients undergoing estrogen therapy].
    Portnoĭ AS; Begunov AV
    Urol Nefrol (Mosk); 1992; (1-3):6-11. PubMed ID: 1413345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Changes in hormonal homeostasis and development of disorders of the cardiovascular system in patients with prostatic cancer on estrogen therapy].
    Gembitskiĭ EV; Begunov AV
    Klin Med (Mosk); 1991 Dec; 69(12):59-63. PubMed ID: 1724022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes in parameters of the coagulation and fibrinolysis system of the blood in patients with prostate cancer in the framework of estrogen therapy].
    Gembitskiĭ EV; Begunov AB
    Klin Med (Mosk); 1994; 72(2):30-2. PubMed ID: 8015238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardiovascular complications during the estrogen therapy of prostatic cancer patients].
    Gonchar MA; Popov AI
    Urol Nefrol (Mosk); 1985; (2):31-3. PubMed ID: 3992753
    [No Abstract]   [Full Text] [Related]  

  • 6. [The cardiovascular and thromboembolic complications of intravital estrogen therapy in middle-aged and elderly patients with prostatic cancer].
    Gorilovskiĭ LM; Makarova GV; Nekliudova VI; Shkhvatsabaia LV
    Urol Nefrol (Mosk); 1992; (1-3):11-5. PubMed ID: 1413332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Porphyria cutanea tarda following treatment with depot estrogens in patients with prostate cancer].
    Linss G; Schmechel C
    Z Urol Nephrol; 1990 May; 83(5):229-31. PubMed ID: 2392882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hypertension associated with stable angina pectoris: favourable interaction between new metoprolol formulation (OROS) and nifedipine.
    Di Somma S; de Divitiis M; Bertocchi F; Carotenuto A; Cudemo G; Petitto M; Napodano M; de Divitiis O
    Cardiologia; 1996 Jul; 41(7):635-43. PubMed ID: 8831181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orchiectomy, estrogen therapy and radiotherapy in locally advanced (T3-4 M0) prostatic cancer.
    Aro J; Haapiainen R; Kajanti M; Rannikko S; Alfthan O
    Scand J Urol Nephrol Suppl; 1988; 110():103-7. PubMed ID: 3187397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening, diagnosis, and treatment of secondary hypertension.
    Weinberger MH
    Compr Ther; 1984 May; 10(5):64-9. PubMed ID: 6734128
    [No Abstract]   [Full Text] [Related]  

  • 12. [Thyroid hormones in metastasizing prostate cancer treated with polyestradiol phosphate].
    Dunzendorfer U; Schulz H
    Z Urol Nephrol; 1982 Jul; 75(7):493-500. PubMed ID: 6183845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Side effects of estrogen administration to prostatic cancer patients: clinical and statistical survey of 109 prostatic cancer cases of Kyoto University Hospital].
    Oishi K; Arai Y; Takeuchi H; Yoshida O
    Hinyokika Kiyo; 1993 Jan; 39(1):23-8. PubMed ID: 8460581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium.
    Mikkola A; Ruutu M; Aro J; Rannikko S; Salo J
    Ann Chir Gynaecol; 1999; 88(1):18-21. PubMed ID: 10230677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Angina pectoris and hypertension].
    Al-Nasser B; Delefosse D; Chhim S
    Rev Odontostomatol (Paris); 1991; 20(5):377-80. PubMed ID: 1811303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Testicular changes during estrogen therapy of prostatic cancer].
    Mihalache G; Adomnicăi G; Adomnicăi M; Iancu I; Mihalache C
    Rev Med Chir Soc Med Nat Iasi; 1986; 90(2):343-5. PubMed ID: 3764207
    [No Abstract]   [Full Text] [Related]  

  • 17. Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group.
    Aro J; Ruutu M; Juusela H; Hansson E; Permi J
    Ann Chir Gynaecol Suppl; 1993; 206():5-8. PubMed ID: 8291869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term effects of captopril treatment on the course of stable effort angina pectoris and structural-functional characteristics of platelets in patients with hypertension and ischemic heart disease].
    Shafer MZh; Gul'tiaeva EP; Gapon LI; Alfimova TV
    Ter Arkh; 2001; 73(7):64-7. PubMed ID: 11523414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The Prinzmetal variant of angina pectoris (author's transl)].
    Scheidemandel V; Heuser R; Obert U
    MMW Munch Med Wochenschr; 1974 Jun; 116(26):1295-8. PubMed ID: 4211708
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk stratification for the prevention of cardiovascular complications of hypertension.
    Girerd X; Giral P
    Curr Med Res Opin; 2004 Jul; 20(7):1137-42. PubMed ID: 15265258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.